Who are Neostigmine + Atropine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Neostigmine+Glycopyrronium.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/neostigmine-atropine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Neostigmine + Atropine — Competitive Intelligence Brief

Neostigmine + Atropine (Neostigmine + Atropine) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cholinesterase inhibitor + Anticholinergic agent. Area: Neurology.

marketed Cholinesterase inhibitor + Anticholinergic agent Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (atropine) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Neostigmine + Atropine (Neostigmine + Atropine) — China Medical University Hospital. Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while atropine blocks muscarinic receptors to counteract excessive parasympathomimetic effects.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Neostigmine + Atropine TARGET	Neostigmine + Atropine	China Medical University Hospital	marketed	Cholinesterase inhibitor + Anticholinergic agent	Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (atropine)
Neostigmine+Glycopyrronium	Neostigmine+Glycopyrronium	Pusan National University Yangsan Hospital	marketed	Acetylcholinesterase inhibitor + Anticholinergic agent	Acetylcholinesterase; Muscarinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cholinesterase inhibitor + Anticholinergic agent class)

China Medical University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Neostigmine + Atropine — Competitive Intelligence Brief. https://druglandscape.com/ci/neostigmine-atropine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab